Phaseline

Companies › KinoTeck Therapeutics

KinoTeck Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Sep 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KNT-0916
FGFR2 inhibitor
FGFR2Phase 1Solid Tumors With FGFR2 Alterations, AdultSep 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06800196KNT-0916Phase 1Solid Tumors With FGFR2 Alterations, AdultOncologySep 2027

Targets

FGFR2 (1)

Companies with the same targets

Tyra Biosciences AstraZeneca Johnson & Johnson (Janssen) Hangzhou Zhongmei Huadong Pharmaceutical Taiho Oncology Elevar Therapeutics BeOne Medicines Exelixis QED Therapeutics, a BridgeBio company TransThera Sciences (Nanjing)

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.